Therapeutic Development
- Small Molecule Drug
- Cell Therapy
- Gene Therapy
- Therapeutic Antibody
- Therapeutic Peptide
- Therapeutic mRNA
- Therapeutic Protein
Immune-Related Skin Diseases are disorders resulting from abnormal immune responses that impair skin function and structure. While each condition is individually rare, together they affect many people worldwide, causing severe symptoms and presenting significant healthcare challenges. Our Company, with expertise in this field, is dedicated to advancing research and developing therapies to address these Immune-Related Skin Diseases.
Immune-Related Skin Diseases are a group of uncommon conditions in which the immune system mistakenly attacks the skin, leading to inflammation and tissue damage. Examples include autoimmune blistering diseases, such as pemphigus and pemphigoid, which have an incidence of 1 to 5 cases per million people per year. These disorders are often chronic and can cause significant morbidity if untreated. Recent advances in immunotherapy have provided new treatment options, though challenges remain in managing these complex conditions.
The pathogenesis of immune-related skin diseases involves complex interactions between genetic predispositions, environmental factors, and immune system dysregulation. Recent studies have revealed that cytokine imbalances and aberrant T-cell activation play critical roles in conditions such as psoriasis and atopic dermatitis.
Advances in understanding the skin microbiome's influence on immune responses highlight its contribution to disease development and exacerbation. Furthermore, cutting-edge genomic and proteomic technologies are providing insights into novel therapeutic targets, offering hope for more effective and personalized therapeutics.
Mesenchymal stem cells (MSC) therapy has shown potential in treating Immune-Related Skin Diseases due to its immunomodulatory and anti-inflammatory properties. MSCs aid in healing skin lesions and promoting re-epithelization by secreting growth factors.
Table.1 Clinical trials of MSC therapy in immune-related skin diseases (Hua, C., S. Chen, and H. Cheng, 2022)
Diseases | Development Stage | Route of Delivery | Type of MSC | ClinicalTrials.gov Identifier |
Psoriasis | Clinical Trial Early Phase 1 | Intravenous infusion. | Human Umbilical Cord-derived Mesenchymal Stem Cells | NCT03765957 |
Clinical Trial Phase 1, 2 | Intravenous infusion. | Human Umbilical Cord-derived Mesenchymal Stem Cells | NCT03745417 | |
Clinical Trial Phase 1, 2 | Subcutaneous injection | Human Umbilical Cord-derived Mesenchymal Stem Cells | NCT02918123 | |
Systemic Sclerosis | Clinical Trial Phase 1 | Intravenous Infusion | Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell | NCT05016804 |
Clinical Trial Phase 1, 2 | Intravenous Infusion | Allogeneic Mesenchymal Stem Cells | NCT00962923 | |
Atopic Dermatitis | Clinical Trial Phase 1 | Intravenous Infusion | Adult human Mesenchymal Stem Cells | NCT02888704 |
Clinical Trial Phase 1 | Intravenous Infusion | Adult human Mesenchymal Stem Cells | NCT03252340 | |
Clinical Trial Phase 3 | Unclear | Human Umbilical Cord Blood derived- Universal Stem Cells | NCT03269773 |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
We provide comprehensive support for developing treatments for rare immune-related skin conditions. Our expert team leverages advanced technology, offering therapeutic development and disease model development services to fast-track your projects.
Therapeutic Development
Disease Model Development
With our deep expertise, we are dedicated to advancing the research and development of treatments for Immune-Related Skin Diseases. Recognizing the unique genetic and pathological features of each condition, our team delivers customized solutions to accelerate the discovery and implementation of effective therapies.
A-L | M-P | S-V |
|
|
|
Our company is focused on providing comprehensive, one-stop preclinical development services to drive the advancement of therapeutics for rare skin diseases. Our integrated solutions simplify the drug development pathway, covering everything from target discovery and disease modeling to thorough drug safety evaluation services and drug metabolism and pharmacokinetics.
If you are interested in our services, please don't hesitate to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.